Organon & Co. (OGN)
| Market Cap | 5.69B |
| Revenue (ttm) | 6.17B |
| Net Income (ttm) | 917.00M |
| Shares Out | 254.38M |
| EPS (ttm) | 3.59 |
| PE Ratio | 6.24 |
| Forward PE | 5.03 |
| Dividend | $1.12 (5.00%) |
| Ex-Dividend Date | Feb 24, 2023 |
| Volume | 2,031,772 |
| Open | 22.59 |
| Previous Close | 22.39 |
| Day's Range | 22.24 - 22.78 |
| 52-Week Range | 21.11 - 39.09 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 33.53 (+49.82%) |
| Earnings Date | May 4, 2023 |
About OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of seve... [Read more]
Financial Performance
In 2022, Organon & Co.'s revenue was $6.17 billion, a decrease of -2.06% compared to the previous year's $6.30 billion. Earnings were $917.00 million, a decrease of -32.12%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for OGN stock is "Buy." The 12-month stock price forecast is $33.53, which is an increase of 49.82% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN
NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contac...
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Building on Organon's Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Exper...
Organon (OGN) Q4 Earnings and Revenues Miss Estimates
Organon (OGN) delivered earnings and revenue surprises of -4.71% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022. "We enter 2023 with momentum, building off the signifi...
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women's healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the c...
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women's healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an in...
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a firesi...
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women's healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will c...
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a firesi...
Organon (OGN) Q3 Earnings and Revenues Top Estimates
Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon Reports Results for the Third Quarter Ended September 30, 2022
JERSEY CITY, N.J.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
JERSEY CITY, N.J.
Jim Cramer gives his take on Organon
Cramer on Tuesday explained his thoughts on pharmaceutical firm Organon.
Drugmaker stocks lead sector with healthy dividends
CNBC's Bertha Coombs reports on health care stocks.
Health care stocks with dividend yields to weather through market turmoil
The healthcare sector is an investor favorite in a defensive market. CNBC's Bertha Coombs joins 'Squawk Box' to break down some players with the best dividend yields.
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
New Strong Sell Stocks for August 8th
COWN, AUD, and OGN have been added to the Zacks Rank #5 (Strong Sell) List on August 8, 2022.
Organon (OGN) Surpasses Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon Reports Results for the Second Quarter Ended June 30, 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports results for the second quarter ended June 30, 2022
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #contraception--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidat...
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #organon--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company's webcast and call scheduled for 8:30 a.m. EDT.